Vaxcyte (PCVX) Corporate presentation summary

Mission and strategic vision

• Aims to engineer high-fidelity vaccines to protect against bacterial diseases globally.

• Focuses on a carrier-sparing, cell-free platform to enable broader-spectrum vaccines.

• Pipeline includes pneumococcal conjugate vaccines (PCVs), Group A Strep, and Shigella candidates.

• Strategic manufacturing partnerships established to support global demand.

• Robust cash position of ~$3.0B to fund development and commercialization.

Market opportunity and disease burden

• Pneumococcal disease remains a leading cause of vaccine-preventable deaths in children under five.

• Global PCV market valued at ~$8B, with significant growth expected, especially in adults.

• Broader-spectrum PCVs are driving new adult vaccination recommendations worldwide.

• Serotype replacement and emerging strains highlight the need for expanded vaccine coverage.

Technology platform and competitive differentiation

• Cell-free protein synthesis platform enables rapid, scalable production of complex proteins.

• Site-specific conjugation allows for consistent antigen presentation and reduced carrier suppression.

• Platform supports both conjugate and novel protein vaccine development.